

Instrumental Support 2493  
 Common Community Resources 2493  
 Internet Resources 2496  
 Language Resources 2498  
 Legal Resources 2498  
 Palliative Care 2498  
 Personal Websites that Facilitate Communication 2498  
 Survivorship 2498  
 Transportation 2498  
 Wish Foundations 2499

## 177. Rehabilitation of the Cancer Patient . . . . 2500

*Michael D. Stubblefield*

The Rehabilitation Team 2500  
 Complications of Cancer and its Treatment 2501  
 Neuromuscular Complications of Cancer and Cancer Treatment 2503  
 Musculoskeletal Complications of Cancer and Cancer Treatment 2510  
 Radiation Fibrosis Syndrome 2513  
 Lymphedema 2518  
 Rehabilitation Interventions 2519  
 Nonpharmacologic Pain Management 2521

---

### Section 21: Societal Issues in Oncology

---

## 178. Regulatory Issues . . . . . 2523

*Ann T. Farrell, Grant A. Williams, and Richard Pazdur*

The History of Food and Drug Administration Regulation of Drugs and Biologics 2523  
 Food and Drug Administration Oversight of Clinical Trials for Drugs and Biologics 2523  
 The Basis for Cancer Drug Approval 2525  
 Drug Safety Reporting and Evaluation 2527  
 Expanded Access to Investigational Drugs 2527  
 Regulation of Devices for Cancer Treatment and Diagnosis 2528

## 179. Health Disparities in Cancer . . . . . 2532

*Harold P. Freeman*

Race and Cancer 2534  
 Relationships Between Culture and Cancer 2535  
 Poverty as a Cause of Cancer Disparities 2535  
 Patient Navigation 2535  
 The Harlem Breast Cancer Experience 2536  
 Discussion 2538  
 What Must be Done to Diminish Cancer Disparities 2538

## 180. Cancer Information on the Internet . . . . . 2540

*Sherri L. Place and J. Robert Beck*

Background 2540  
 Tools for Finding Information 2540  
 Evaluating Information 2541  
 Search Strategies 2543  
 Useful Tools for Keeping Up 2544

---

### Section 22: Complementary, Alternative, and Integrative Therapies

---

## 181. Complementary, Alternative, and Integrative Therapies in Cancer Care. . . . . 2550

*Catherine Ulbricht, Lorenzo Cohen, and Richard Lee*

Background 2550  
 Establishing an Integrative Oncology Approach with Patients 2550  
 Standardization and Quality 2555  
 Specific Complementary and Alternative Medicine Therapies 2556

*Index* 2563

Effects of Cytotoxic Agents on Children 2378  
 Gonadal Dysfunction After Cranial Irradiation 2378  
 Preservation of Fertility, Hormone Levels, and Sexual Function 2378  
 Pharmacologic Attempts at Preserving Fertility in Men 2382  
 Pharmacologic Attempts at Preserving Fertility in Women 2382  
 Fertility Preservation in Women with Cervical Cancer 2384  
 Evaluation of Fertility After Treatment 2384  
 Hormone Replacement Therapy 2384  
 Prevention and Management of Erectile and Ejaculatory Dysfunction 2384  
 Genetic Concerns 2385

**166. Fatigue . . . . . 2387**

*Sandra A. Mitchell and Ann M. Berger*

Definition and Etiology of Cancer-Related Fatigue 2387  
 Current Theories of Cancer-Related Fatigue 2387  
 Evaluation of the Patient with Cancer-Related Fatigue 2388  
 Interventions for Fatigue 2389

**167. Second Primary Cancers . . . . . 2393**

*Lois B. Travis, Smita Bhatia, James M. Allan, Kevin C. Oeffinger, and Andrea Ng*

Methods to Assess Second Cancer Risk 2393  
 Carcinogenicity of Individual Treatment Modalities 2394  
 Genetic Susceptibility to Second Primary Cancers 2396  
 Risk of Second Malignancy in Patients with Selected Primary Cancers 2398  
 Pediatric Malignancies 2406  
 Comment 2409

**168. Neurocognitive Effects . . . . . 2411**

*Paul D. Brown, Nadia N. I. Laack, and Jeffrey S. Wefel*

Assessment of Neurocognitive Function 2411  
 Impact of Treatment 2412  
 Impact of Tumor 2415  
 Treatment of Cognitive Dysfunction 2415

**169. Cancer Survivorship . . . . . 2418**

*Wendy Landier, Craig C. Earle, Smita Bhatia, Melissa M. Hudson, Kevin Oeffinger, Patricia A. Ganz, and Louis S. Constine*

Definition of Survivorship and Scope of the Problem 2418  
 Goals of Survivorship Health Care 2419  
 Care Plans 2422  
 Delivery of Follow-Up Care and Best-Practice Models 2423  
 Educational Considerations 2423  
 Enhancing Research 2423  
 Survivorship Advocacy 2424

**Section 20: Supportive Care and Quality of Life**

**170. Management of Cancer Pain . . . . . 2426**

*Amy Abernathy and Kathleen M. Foley*

Epidemiology 2426  
 Definition of Pain 2427  
 Common Pain Syndromes 2429  
 Management of Cancer Pain 2432  
 Psychological Approaches 2442  
 Anesthetic and Neurosurgical Approaches 2442  
 Neuropharmacologic Approaches 2445  
 Neuroablative and Neurostimulatory Procedures for the Relief of Pain 2445  
 Trigger Point Injection and Acupuncture 2445  
 Psychiatric Approaches 2446  
 Algorithm for Cancer Pain Management 2446  
 Future Directions 2446

**171. Nutritional Support . . . . . 2448**

*Alessandro Laviano, Robert A. Meguid, and Michael M. Meguid*

Anorexia 2448  
 Changes in Host Metabolism: Weight Loss and Cachexia 2449  
 Nutrition Therapy for Cancer Cachexia 2450  
 Nutrition and Tumor Growth 2450  
 Nutritional Assessment of the Cancer Patient 2451  
 Parenteral Versus Enteral Nutrition in Cancer Patients 2451  
 Ethical and Legal Aspects of Nutrition Therapy 2454

**172. Sexual Problems . . . . . 2456**

*Veronica Sanchez Varela, Christian J. Nelson, and Sharon L. Bober*

Cancer in Men 2456  
 Cancers that Affect Men and Women 2458  
 Cancer in Women 2460  
 Cancer in Children and Young Adults 2463  
 Relevant Sociocultural Considerations 2463  
 Disruption of Intimacy and Relational Considerations 2464

**173. Psychological Issues in Cancer . . . . . 2467**

*David Spiegel and Michelle B. Riba*

Understanding Cancer as a Trauma 2467  
 Common Psychiatric Conditions 2467  
 Screening for Psychological Problems 2467  
 Coping 2469  
 Treatment Interventions 2469  
 Outcome 2472  
 Implications for Cancer Progression and Mortality 2472  
 Survivorship 2472  
 Psychotropic Medication 2473

**174. Communicating News to the Cancer Patient . . . . . 2477**

*Eric J. Cassell*

Preventing Illness 2477  
 Communication 2477  
 Explanations 2478  
 Uncomfortable Questions 2479  
 Information 2479  
 Meaning 2479  
 Cafeteria Explanations 2480

**175. Specialized Care of the Terminally Ill . . . . 2481**

*Kristen G. Schaefer, Kathy Selvaggi, and Janet L. Abraham*

Discussing Prognosis 2481  
 Discussing End of Life 2481  
 Hope 2482  
 Healing Versus Curing 2482  
 How to Tell the Children 2482  
 Cultural and Religious Considerations 2482  
 Care without Chemotherapy 2483  
 Palliative Care Programs 2483  
 Hospice Programs 2483  
 Relief of Suffering 2483  
 The Final Days 2488  
 After the Death 2488  
 Grief and Bereavement 2488

**176. Community Resources . . . . . 2491**

*Bonnie A. Indeck and Nora Rughtmer*

Community Resources for the Cancer Patient and Family 2491  
 The Cancer Patient 2491  
 Social and Emotional Support 2491  
 Informational Support 2492

- Paraneoplastic Syndromes with Muscle Rigidity 2234  
 Dermatomyositis 2234  
 Movement Disorders 2234  
 Approach to the Patient with Paraneoplastic  
 Neurologic Disease 2234

### Section 18: Stem Cell Transplantation

#### 154. Autologous Stem Cell Transplantation . . . 2236

*John Magenau, Dale Bixby, and James Ferrara*

- History 2236  
 Stem Cell Mobilization 2236  
 Inadequate Mobilization of Stem Cells 2237  
 Tumor Contamination 2237  
 Indication and Timing of Autologous Hematopoietic Stem Cell  
 Transplantation 2237  
 Standard Infection Prophylaxis 2238  
 High-Dose Conditioning Regimens 2239  
 Complications of Autologous Hematopoietic Stem Cell  
 Transplantation 2239  
 Recent Developments in Autologous Hematopoietic Stem Cell  
 Transplantation 2241  
 Future Directions 2241

#### 155. Allogeneic Stem Cell Transplantation . . . 2244

*Richard W. Childs*

- Conditioning Regimens 2244  
 Graft-Versus-Leukemia Effect 2245  
 Mechanisms of Graft-Versus-Leukemia Effect 2246  
 Complications of Allogeneic Hematopoietic Stem Cell  
 Transplantation 2247  
 Veno-Occlusive Disease 2247  
 Epstein-Barr Virus Lymphoproliferative Disorder 2248  
 Sources of Allogeneic Hematopoietic Stem Cells 2251  
 Results of Conventional Allogeneic Transplantation for  
 Hematologic Malignancies 2254  
 Future Prospects 2260

### Section 19: Management of Adverse Effects of Treatment

#### 156. Infections in the Cancer Patient . . . . . 2262

*Juan Gea-Banacloche and Brahm H. Segal*

- RISK FACTORS FOR INFECTIONS IN  
 PATIENTS WITH CANCER AND ANTIMICROBIAL  
 PROPHYLAXIS 2262  
 Risk Factors for Infection 2262  
 Prevention of Infections 2266  
 DIAGNOSIS AND MANAGEMENT OF INFECTIOUS DISEASES  
 SYNDROMES 2272  
 Fever and Neutropenia 2272  
 SELECTED PATHOGENS OF INTEREST IN ONCOLOGY 2291  
 Selected Bacterial Infections in Patients with Cancer 2291

#### 157. Leukopenia and Thrombocytopenia. . . . . 2300

*Carla Kurkjian and Howard Ozer*

- Overview of Hematopoiesis and Hematopoietic  
 Growth Factors 2300  
 Erythropoietin 2300  
 Granulocyte Colony-Stimulating Factor 2301  
 Granulocyte-Macrophage Colony-Stimulating Factor 2304  
 Interleukin-11 2304  
 Thrombopoietin Agents 2305  
 Clinical Use of Erythropoietin-Stimulating Agents in  
 Cancer Therapy 2305  
 Clinical Use of Recombinant Granulocyte Colony-Stimulating  
 Factors in Cancer Therapy 2307  
 Use of Colony-Stimulating Factors in other Oncology Settings 2309  
 Clinical Use of Thrombopoietin Agents 2311

#### 158. Cancer-Associated Thrombosis . . . . . 2314

*Agnes Y. Y. Lee and Alok A. Khorana*

- Mechanisms of Cancer-Associated Thrombosis 2314  
 Epidemiology of Cancer-Associated Thrombosis 2314  
 Prevention of Cancer-Associated Thrombosis 2316  
 Treatment of Cancer-Associated Thrombosis 2317

#### 159. Nausea and Vomiting. . . . . 2321

*Elizabeth M. Blanchard and Paul J. Hesketh*

- Nausea and Vomiting Syndromes 2321  
 Pathophysiology of Treatment-Induced Nausea and Vomiting 2321  
 Defining the Risk of Nausea and Vomiting 2322  
 Antiemetic Agents 2323  
 Antiemetic Treatment by Clinical Setting 2326  
 Special Chemotherapy-Induced Nausea and Vomiting Problems 2326  
 Radiotherapy-Induced Nausea and Vomiting 2327

#### 160. Diarrhea and Constipation . . . . . 2329

*Nathan I. Cherny*

- Diarrhea 2329  
 Constipation 2333

#### 161. Oral Complications . . . . . 2337

*Eliezer Soto, Jane M. Fall-Dickson, and Ann M. Berger*

- Oral Mucositis 2337  
 Chemotherapy-Induced Stomatitis 2337  
 Radiation-Induced Stomatitis 2337  
 Radiation Therapy-Related Complications 2338  
 Pathogenesis of Chemotherapy- and Radiation-Induced  
 Oral Mucositis 2338  
 Chronic Graft-Versus-Host Disease Oral Manifestations 2339  
 Sequelae of Oral Complications 2339  
 Strategies for Prevention and Treatment of Oral Complications 2340  
 Treatment Strategies 2340  
 Radioprotectors 2342  
 Biological Response Modifiers 2343  
 Treatment for Oral Chronic Graft-Versus-Host Disease 2344  
 Symptom Management 2345

#### 162. Pulmonary Toxicity . . . . . 2348

*Diane E. Stover and Robert J. Kaner*

- Radiation-Induced Pulmonary Toxicity 2348  
 Chemotherapy-Induced Pulmonary Toxicity 2351

#### 163. Cardiac Toxicity . . . . . 2360

*Joachim Yahalom and Carol S. Portlock*

- Anthracyclines 2360  
 Cyclophosphamide 2362  
 Ifosfamide 2362  
 Taxanes 2362  
 Trastuzumab 2363  
 Fluoropyrimidines 2363  
 Tyrosine Kinase Inhibitors 2364  
 Radiation-Induced Heart Disease 2364  
 Future Directions 2367

#### 164. Hair Loss. . . . . 2368

*Joyson J. Karakunnel and Ann M. Berger*

- Anatomy and Physiology 2368  
 Classification 2368  
 Diagnosis 2369  
 Treatment 2369

#### 165. Gonadal Dysfunction. . . . . 2372

*John M. Norian, Eve C. Feinberg, Alan H. DeCherney, and  
 Alicia Y. Armstrong*

- Effects of Cytotoxic Agents on Adult Men 2372  
 Effects of Cytotoxic Agents on Adult Women 2374

Pathogenesis of AK	1615
Clinical Features of AK	1615
Treatment of AK	1615
BASAL CELL CARCINOMA	1616
Clinical Behavior of BCC	1617
BCC Subtypes	1617
Histology	1618
Treatment	1619
SQUAMOUS CELL CARCINOMA	1620
Pathogenesis of SCC	1620
Biologic Behavior of SCC	1620
Clinical Features of SCC	1621
Histology	1621
Recurrence and Metastatic Risk	1621
Treatment	1622
Follow Up	1623
Immunosuppression and Nonmelanoma Skin Cancer	1623
ANGIOSARCOMA	1624
Pathogenesis	1624
Clinical Presentation and Prognosis	1624
Histology	1625
Treatment	1625
DERMATOFIBROSARCOMA PROTUBERANS	1625
Pathogenesis	1625
Histology	1625
Treatment	1625
Recurrence and Metastatic Potential	1626
MERKEL CELL CARCINOMA	1626
Pathogenesis	1626
Clinical Presentation	1626
Histology	1626
Treatment	1627
Staging	1627
Recurrence and Metastatic Risk	1627
Prognosis	1628
MICROCYSTIC ADNEXAL CARCINOMA	1628
Pathogenesis	1629
Clinical Presentation	1629
Histology	1629
Treatment	1629
SEBACEOUS CARCINOMA	1629
Histology	1630
Treatment	1630
ATYPICAL FIBROXANTHOMA AND MALIGNANT FIBROUS HISTIOCYTOMA	1630
ATYPICAL FIBROXANTHOMA	1630
Pathogenesis	1630
Clinical Presentation	1630
Histology	1631
Treatment	1631
MALIGNANT FIBROUS HISTIOCYTOMA	1631
Clinical Presentation	1631
Histology	1631
Treatment and Prognosis	1631
CARCINOMA METASTATIC TO SKIN	1631
<b>118. Molecular Biology of Cutaneous Melanoma . . . . .</b>	<b>1634</b>
<i>Levi A. Garraway and Lynda Chin</i>	
The CDKN2A Locus	1634
The Retinoblastoma Pathway	1634
The p53 Pathway	1635
The MAP Kinase Pathway	1636
The RAS Family: H-, N-, and K-RAS	1636
The Phosphatidylinositol 3-Kinase Pathway	1638
Receptor Tyrosine Kinases	1638
Epidermal Growth Factor Receptor Family	1639
The MITF Pathway	1639
The WNT Pathway	1639
The MC1R Pathway	1640
The FAK Pathway	1640
Cancer Stem Cells and Melanoma	1640
Cancer Genomics and Translation	1640
Looking Ahead	1641

## 119. Cutaneous Melanoma . . . . . 1643

*Craig L. Slingluff Jr., Keith Flaherty, Steven A. Rosenberg, and Paul W. Read*

Cutaneous Melanoma Biology	1643
Epidemiology	1644
Changes in Incidence	1645
Gender and Age Distribution	1645
Melanoma in Children, Infants, and Neonates	1645
Anatomic Distribution	1646
Etiology and Risk Factors	1646
Pregnancy and Estrogen Use	1646
Prevention and Screening	1647
Diagnosis of Primary Melanoma	1648
General Considerations in Clinical Management of a Newly Diagnosed Cutaneous Melanoma (Stage I–II)	1652
Wide Local Excision for Clinical Stage I–II Melanoma: General Considerations	1653
Clinical Trials to Define Margins of Excision for Primary Cutaneous Melanomas	1653
Surgical Staging of Regional Nodes	1655
Management of Clinically Localized Melanoma	1658
Management of Thin Primary Melanoma (Clinical T1a)	1658
Management of Clinical T2a, T2b Melanomas	1660
Management of Clinical T3a Melanomas (Clinical Stage IIA)	1660
Management of Clinical T3b Melanomas (Clinical Stage IIB)	1660
Management of Thick Melanomas (T4a, T4b, Greater than 4 mm Thick)	1660
Special Considerations in Management of Primary Melanomas	1661
The Role of Radiation Therapy in the Management of Primary Melanoma Lesions	1662
Clinical Follow-Up for Intermediate-Thickness and Thick Melanomas (Stage IB–IIC)	1662
Regionally Metastatic Melanoma (Stage III): Lymph Node Metastasis, Satellite Lesions, and In-Transit Metastases	1662
Management of Regional Metastases in Patients with Visceral or Other Distant Disease	1666
Adjuvant Systemic Therapy (Stages IIB, IIC, and III)	1667
Management of Distant Metastases of Melanoma (Stage IV)	1672
Combination Chemotherapy	1678
Experimental and Developing Immunologic Therapies for Stage IV Melanoma	1682
Rationale for Targeted Therapy in Melanoma	1684
Radiation Therapy for Metastatic Melanoma (Stage IV)	1687

## Section 10: Neoplasms of the Central Nervous System

### 120. Molecular Biology of Central Nervous System Tumors. . . . . 1692

*C. David James, David N. Louis, and Webster K. Cavenee*

Neurologic Tumor Syndromes	1692
CNS Tumor Histopathology and Molecular Correlates	1692
Current Basis of CNS Tumor Treatment and Response to Therapy	1698

### 121. Neoplasms of the Central Nervous System 1700

*Minesh Mehta, Michael A. Vogelbaum, Susan Chang, and Neha Patel*

Epidemiology of Brain Tumors	1700
Anatomic Location and Clinical Considerations	1702
Neurodiagnostic Tests	1705
Surgery	1706
Radiation Therapy	1708
Chemotherapy and Targeted Agents	1710
Specific Central Nervous System Neoplasms	1712
Gliomatosis Cerebri	1720
Optic, Chiasm, and Hypothalamic Gliomas	1720
Brainstem Gliomas	1722
Cerebellar Astrocytomas	1723
Gangliogliomas	1723
Ependymoma	1724

Diagnosis and Biopsy 1407  
 Lobular Carcinoma *In Situ* 1408  
 Ductal Carcinoma *In Situ* 1409  
 Treatment of the Breast 1409  
 Treatment of the Axilla 1411  
 Endocrine Therapy 1411  
 Staging 1411  
 Pathology of Breast Cancer 1413  
 Local Management of Invasive Cancer 1414  
 Breast-Conserving Therapy 1414  
 Mastectomy 1422  
 Management of the Axilla 1423  
 Local-Regional Therapy and Survival 1425  
 Prognostic and Predictive Factors 1426  
 Other Factors 1427  
 Molecular and Genomic Factors 1427  
 Adjuvant Systemic Therapy 1428  
 Integration of Multimodality Primary Therapy 1434  
 Follow-Up for Breast Cancer Survivors 1435  
 Special Therapeutic Problems 1436  
 Metastatic Disease 1439

**Section 7: Cancer of the Endocrine System**

**107. Molecular Biology of Endocrine Tumors . 1447**

*Samuel A. Wells, Jr.*  
 The Multiple Endocrine Neoplasia Syndromes 1447  
 Application of Molecular Genetics to Clinical Medicine 1452  
 Sporadic Thyroid Cancers 1453  
 Future Directions 1455

**108. Thyroid Tumors.....1457**

*Tobias Carling and Robert Udelsman*  
 Thyroid Tumor Classification and Staging Systems 1457  
 Epidemiology and Demographics 1458  
 Etiology and Risk Factors 1458  
 Evaluation of the Thyroid Nodule 1460  
 Well-Differentiated Thyroid Carcinoma 1462  
 Treatment of Well and Intermediately Differentiated Thyroid Carcinoma 1464  
 Poorly Differentiated Thyroid Carcinoma 1468  
 Medullary Thyroid Carcinoma 1469  
 Treatment of Familial Medullary Thyroid Carcinoma 1470  
 Thyroid Lymphoma 1470  
 Metastatic Disease of the Thyroid 1471  
 Children with Thyroid Carcinoma 1471

**109. Parathyroid Tumors..... 1473**

*Reza Rabbari and Electron Kebebew*  
 Epidemiology 1473  
 Pathology 1474  
 Molecular Genetics 1475  
 Clinical Manifestations 1475  
 Diagnosis 1475  
 Management of Parathyroid Cancer 1476  
 Follow-Up and Natural History 1477  
 Prognosis 1478

**110. Adrenal Tumors..... 1480**

*Mio Kitano, Erin Patterson, and Electron Kebebew*  
 Adrenocortical Cancer 1480  
 Pediatric Adrenocortical Carcinoma 1484  
 Pheochromocytoma 1484  
 Adrenal Incidentaloma 1487

**111. Pancreatic Neuroendocrine Tumors..... 1489**

*James C. Yao, Guido Rindi, and Douglas B. Evans*  
 Epidemiology 1489  
 Classification, Histopathology, and Molecular Genetics 1489  
 Diagnosis and Management of Pancreatic Endocrine Tumors 1492

Additional Clinical Considerations 1499  
 Surgery Pitfalls 1500  
 Emerging Therapeutic Options 1501

**112. Neuroendocrine (Carcinoid) Tumors and the Carcinoid Syndrome ..... 1503**

*Gerard M. Doherty*  
 Pathology and Tumor Histology 1503  
 Molecular Pathogenesis 1506  
 Clinical Features of Carcinoid Tumors 1506  
 Carcinoid Syndrome 1506  
 Treatment of the Carcinoid Tumor 1512

**113. Multiple Endocrine Neoplasias ..... 1516**

*Gerard M. Doherty*  
 Multiple Endocrine Neoplasia Type 1 1516  
 Familial Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Types 2A and 2B 1519

**Section 8: Sarcomas of Soft Tissue and Bone**

**114. Molecular Biology of Soft Tissue Sarcoma 1522**

*Samuel Singer, Torsten Nielsen, and Cristina R. Antonescu*  
 Translocation-Associated Sarcomas 1522  
 Simple Karyotype Tumors Associated with Mutations 1528  
 Complex Sarcoma Types 1528  
 Future Directions: Functional Screens and Next-Generation Sequencing 1531

**115. Soft Tissue Sarcoma..... 1533**

*Samuel Singer, Robert G. Maki, and Brian O'Sullivan*  
 Incidence and Etiology 1533  
 Anatomic and Age Distribution and Pathology 1535  
 Diagnosis and Staging 1547  
 Management by Presentation Status, Extent of Disease, and Anatomic Location 1552  
 Palliative Care 1574  
 Future Directions 1576

**116. Sarcomas of Bone ..... 1578**

*Martin M. Malawer, Lee J. Helman, and Brian O'Sullivan*  
 Classification and Types of Bone Tumor 1578  
 Radiographic Evaluation and Diagnosis 1578  
 Natural History 1579  
 Staging Bone Tumors 1581  
 Preoperative Radiographic Evaluation 1581  
 Biopsy Technique and Timing 1585  
 Restaging After Induction (Preoperative) Chemotherapy 1585  
 Guidelines for Limb-Sparing Resection 1586  
 Types of Skeletal Reconstruction 1586  
 Limb-Sparing Surgery and Perioperative Pain Management 1587  
 Amputations 1588  
 Chemotherapy for Bone Sarcomas 1589  
 Radiotherapy for Osteosarcoma 1594  
 Malignant Bone Tumors 1595

**Section 9: Cancers of the Skin**

**117. Cancer of the Skin ..... 1610**

*Anetta Reszko, Sumaira Z. Aasi, Lynn D. Wilson, and David J. Leffell*  
 NONMELANOMA SKIN CANCER 1610  
 Diagnosis 1610  
 General Approach to Management of Skin Cancer 1610  
 Topical Therapy for Skin Cancer 1613  
 Radiation Therapy for Skin Cancer 1614  
 ACTINIC KERATOSES 1614

Information from Expression and Genomic Microarray Profiling 1188  
 Signaling Pathways in Urothelial Carcinoma 1189  
 Urothelial Tumor-Initiating Cells 1189  
 Molecular Pathogenesis and Tumor Clonality 1189

## 95. Cancer of the Bladder, Ureter, and Renal Pelvis . . . . . 1192

*W. Scott McDougal, William U. Shipley, Donald S. Kaufman, Douglas M. Dahl, M. Dror Michaelson, and Anthony L. Zietman*

Urothelial Cancers 1192  
 Cancer of the Bladder 1194  
 Cancers of the Renal Pelvis and Ureter 1205

## 96. Molecular Biology of Prostate Cancer . . . 1212

*Yu Chen, Vivek K. Arora, and Charles L. Sawyers*

Genetic Predisposition 1212  
 Genetic Landscape of Prostate Cancer 1212  
 ETS Transcription Factors 1216

## 97. Cancer of the Prostate . . . . . 1220

*Michael J. Zelefsky, James A. Eastham, and A. Oliver Sartor*

Anatomy of the Prostate 1220  
 Prostate Zonal Anatomy 1220  
 Histopathology 1220  
 Gleason Score 1222  
 Incidence, Epidemiology, and Risk Factors 1222  
 Incidence and Mortality of Prostate Cancer 1223  
 Clinical Risk Factors for Prostate Cancer 1223  
 Genetic Alterations and Risk 1224  
 Prostate Cancer Prevention 1224  
 Disease Presentation and Diagnosis 1227  
 Staging Workup 1228  
 Prognostic Factors and the Assessment of Risk 1230  
 Treating Clinically Localized Prostate Cancer 1231  
 External-Beam Radiotherapy 1238  
 Androgen Deprivation and Radiation Therapy 1249  
 Adjuvant Radiation Therapy for High-Risk Patients After Radical Prostatectomy 1252  
 Management of the Rising PSA After Definitive Local Therapy 1253  
 Management of Metastatic Prostate Cancer 1258  
 Castration-Resistant Prostate Cancer 1262

## 98. Cancer of the Urethra and Penis. . . . . 1272

*Edouard J. Trabulsi and Leonard G. Gomella*

Cancer of the Male Urethra 1272  
 Carcinoma of the Female Urethra 1273  
 Cancer of the Penis 1274

## 99. Cancer of the Testis . . . . . 1280

*George J. Bosl, Darren R. Feldman, Dean F. Bajorin, Joel Sheinfeld, Robert J. Motzer, Victor E. Reuter, Marisa A. Kollmeier, and Raju S. K. Chaganti*

Background: Incidence 1280  
 Epidemiology 1280  
 Risk Factors 1280  
 Initial Presentation and Management 1280  
 Histology 1281  
 Biology 1282  
 Immunohistochemical Markers 1284  
 Staging 1284  
 Management of Clinical Stage I Disease 1286  
 Management of Clinical Stage II (Low Tumor Burden) 1290  
 Management of Stage II and Stage III Disease (High Tumor Burden) 1291  
 Management of Relapse and Refractory Disease 1296  
 Treatment Sequelae 1298  
 Long-Term Follow-Up 1299  
 Midline Tumors of Uncertain Histogenesis 1299  
 Other Testicular Tumors 1299

## Section 5: Gynecologic Cancers

### 100. Molecular Biology of Gynecologic Cancers . . . . . 1302

*Kunle Odunsi, Tanja Pejovic, and Matthew L. Anderson*

Ovarian Cancer 1302  
 Endometrial Cancer 1306  
 Cervix, Vaginal, and Vulvar Cancers 1307  
 Gestational Trophoblastic Disease 1309

### 101. Cancer of the Cervix, Vagina, and Vulva . . . . . 1311

*Patricia J. Eifel, Jonathan S. Berek, and Maurie A. Markman*

Carcinoma of the Cervix 1311  
 Carcinoma of the Vagina 1330  
 Carcinoma of the Vulva 1335

### 102. Cancers of the Uterine Body . . . . . 1345

*Pedro T. Ramirez, Arno J. Mundt, and Franco M. Muggia*

Endometrial Carcinoma 1345  
 Uterine Sarcomas 1356

### 103. Gestational Trophoblastic Neoplasms . . . 1363

*Donald P. Goldstein and Ross S. Berkowitz*

Epidemiology 1363  
 Pathology and Natural History 1363  
 Indications for Treatment 1363  
 Measurement of hCG 1364  
 Phantom hCG 1364  
 Pretreatment Evaluation 1364  
 Staging and Prognostic Score 1364  
 Treatment 1364  
 Placental Site Trophoblastic Tumors 1366  
 Subsequent Pregnancy 1366  
 Psychosocial Issues 1366

### 104. Ovarian Cancer, Fallopian Tube Carcinoma, and Peritoneal Carcinoma. . . . . 1368

*Stephen A. Cannistra, David M. Gershenson, and Abram Recht*

Epithelial Ovarian Cancer 1368  
 Borderline Tumors 1385  
 Germ Cell Tumors of the Ovary 1386  
 Sex Cord–Stromal Tumors 1387  
 Primary Peritoneal Serous Carcinoma 1389  
 Fallopian Tube Cancer 1389

## Section 6: Cancer of the Breast

### 105. Molecular Biology of Breast Cancer . . . . 1392

*Erin Wysong Hofstatter, Gina G. Chung, and Lyndsay N. Harris*

Genetics of Breast Cancer 1392  
 Hereditary Breast Cancer 1392  
 Somatic Changes in Breast Cancer 1393  
 Gene Expression Patterns in Breast Cancer 1395  
 Epigenetics of Breast Cancer 1396  
 Protein/Pathway Alterations 1397

### 106. Malignant Tumors of the Breast . . . . . 1401

*Harold J. Burstein, Jay R. Harris, and Monica Morrow*

Anatomy of the Breast 1401  
 Risk Factors for Breast Cancer 1401  
 Benign Breast Disease 1404  
 Breast Density 1404  
 Environmental Factors 1404  
 Management of the High-Risk Patient 1404

Meningiomas	1727
Primitive Neuroectodermal or Embryonal Central Nervous System Neoplasms	1730
Pineal Region Tumors and Germ Cell Tumors	1733
Pituitary Adenomas	1735
Craniopharyngiomas	1737
Vestibular Schwannomas	1738
Glomus Jugulare Tumors	1740
Hemangioblastomas	1741
Chordomas and Chondrosarcomas	1742
Choroid Plexus Tumors	1744
Spinal Axis Tumors	1745

---

## Section 11: Cancers of Childhood

---

### 122. Molecular Biology of Childhood Cancers . . . 1750

*Lee J. Helman and David Malkin*

Tumor Suppressor Genes	1750
Retinoblastoma: The Paradigm	1752
Wilms Tumor: Three Distinct Loci	1753
Neurofibromatosis	1753
Neuroblastoma	1754
Ewing Sarcoma Family of Tumors	1755
Rhabdomyosarcoma	1755
Hereditary Syndromes Associated with Tumors of Childhood	1756
Malignant Rhabdoid Tumors	1757
Predictive Testing for Germ Line Mutations and Childhood Cancers	1757
Molecular Therapeutics	1758

### 123. Solid Tumors of Childhood . . . . . 1760

*Lisa L. Wang, Jason Yustein, Chrystal Louis, Heidi V. Russell, Alberto S. Pappo, Arnold Paulino, Jed G. Nuchtern, and Murali Chintagumpala*

The Importance of Multidisciplinary Management Teams in Pediatric Solid Tumors	1760
Neuroblastoma	1760
Wilms' Tumor	1766
Retinoblastoma	1769
Pediatric Bone Sarcomas: Osteosarcoma and Ewing's Sarcoma	1771
Rhabdomyosarcoma	1780
Liver Tumors	1784
Germ Cell Tumors	1786

### 124. Leukemias and Lymphomas of Childhood . . . . . 1793

*Judith F. Margolin, Karen R. Rabin, and David G. Poplack*

Leukemias	1793
Lymphomas	1801
Supportive Care	1804
Long-Term, Palliative, and Hospice Care in Pediatric Oncology	1804

---

## Section 12: Lymphomas in Adults

---

### 125. Molecular Biology of Lymphomas . . . . . 1806

*Urban Novak, Laura Pasqualucci, and Riccardo Dalla-Favera*

The Cell of Origin of Lymphoma	1806
General Mechanisms of Genetic Lesion in Lymphoma	1807
Molecular Pathogenesis of B-Cell Non-Hodgkin's Lymphoma	1810
Molecular Pathogenesis of T-Cell NHL	1816
Molecular Pathogenesis of HL	1817

### 126. Hodgkin Lymphoma . . . . . 1819

*Andreas Engert, Dennis A. Eichenauer, Nancy Lee Harris, Peter M. Mauch, and Volker Diehl*

History of Hodgkin Lymphoma	1819
Etiology and Epidemiology	1819
Biology and Cell of Origin	1820
Immunology of Hodgkin Lymphoma	1820

Diagnosis and Staging of Hodgkin Lymphomas	1825
Clinical Presentation of Hodgkin Lymphomas	1827
Treatment Methods for Hodgkin Lymphoma	1827
Choice of Treatment	1829
Treatment for Early Favorable Hodgkin Lymphoma	1832
Early Unfavorable Hodgkin Lymphoma	1834
Advanced Stages of Hodgkin Lymphoma	1836
Progressive and Relapsed Disease	1840
Lymphocyte-Predominant Hodgkin Lymphoma	1844
Special Populations	1846
Treatment-Related Late Side Effects	1848
Quality of Life	1850
New Drugs in Hodgkin Lymphoma	1851

### 127. Non-Hodgkin Lymphomas . . . . . 1851

*Jonathan W. Friedberg, Peter M. Mauch, Lisa Rimsza, and Richard I. Fisher*

Epidemiology	1855
Etiology	1855
Biologic Background for Classification of Lymphoid Neoplasms	1857
B- and T-Cell Differentiation	1857
Immunophenotyping of Lymphoid Cells	1862
Chromosomal Translocations and Oncogene Rearrangements	1863
Use of Immunophenotyping and Genetic Studies in the Diagnosis of Lymphoid Neoplasms	1864
Principles of the World Health Organization Classification of Lymphoid Neoplasms	1864
Principles of Management of Non-Hodgkin Lymphoma	1867
Specific Disease Entities	1869
Mature T-Cell and NK Cell Neoplasms	1884
Special Clinical Situations	1889

### 128. Cutaneous Lymphomas . . . . . 1894

*Francine M. Foss, Richard L. Edelson, and Lynn D. Wilson*

Mycosis Fungoides and the Sézary Syndrome	1894
Diagnosis and Staging	1896
Clinical Evaluation of Patients with Cutaneous Lymphoma	1898
Principles of Therapy of Mycosis Fungoides and the Sézary Syndrome	1899
Systemic Therapy for Mycosis Fungoides and the Sézary Syndrome	1902
Other Cutaneous Lymphomas	1905

### 129. Primary Central Nervous System Lymphoma . . . . . 1908

*Lisa M. DeAngelis and Joachim Yabalom*

Clinical Features	1908
Diagnostic Tests	1909
Pathology	1909
Management and Therapy	1910

---

## Section 13: Leukemias and Plasma Cell Tumors

---

### 130. Molecular Biology of Acute Leukemias . . . . . 1916

*Glen D. Raffel and Jan Cerny*

Leukemic Stem Cell	1916
Elucidation of Genetic Events in Acute Leukemia	1916
Recurring Chromosomal Abnormalities in Acute Leukemia	1917
Chromosomal Translocations that Target Core-Binding Factor	1917
Chromosomal Translocations that Target the Retinoic Acid Receptor Alpha Gene	1919
Chromosomal Translocations that Target HOX Family Members	1920
Chromosomal Translocations that Target the MLL Gene	1920
Chromosomal Translocations that Involve Transcriptional Coactivators and Chromatin Remodeling Proteins	1921

**63. Genetic Counseling . . . . . 631***Ellen T. Matloff and Danielle Campfield Bonadies*

- Who is a Candidate for Cancer Genetic Counseling? 631  
 Components of the Cancer Genetic Counseling Session 632  
 Issues in Cancer Genetic Counseling 635  
 Future Directions 637

**PART SEVEN****SPECIALIZED TECHNIQUES IN  
CANCER MANAGEMENT****64. Vascular Access and Specialized  
Techniques . . . . . 640***James F. Pingpank, Jr.*

- Catheter Types 640  
 Catheter Selection 643  
 Pediatric Patients 643  
 Insertion Techniques 643  
 Catheter-Related Complications 645

**65. Interventional Radiology . . . . . 648***Christos S. Georgiades and Jean-Francois H. Geschwind*

- Pulmonary 648  
 Hepaticobiliary 649  
 Cholangiocarcinoma 652  
 Liver Metastases 655  
 Genitourinary 657  
 Musculoskeletal Cancer 659  
 Special Topic: Inferior Vena Cava/Portal Vein  
 Occlusion 661

**66. Functional Imaging . . . . . 666***Brian D. Ross, Craig J. Galbán, and  
Ahawaz Rehemtulla*

- Diffusion Magnetic Resonance Imaging 666  
 Perfusion Magnetic Resonance Imaging 670  
 Magnetic Resonance Spectroscopy 672

**67. Molecular Imaging . . . . . 676***Steven M. Larson, Heiko Schöder, and Jan Grimm*

- Characterizing the Cancer Cell Phenotype 676  
 Clinical Applications 680  
 Optical Imaging 683

**68. Photodynamic Therapy . . . . . 686***Keith A. Cengel, Smith Apisarnthanarax, and  
Stephen M. Hahn*

- Components of Photodynamic Therapy: Photosensitizers,  
 Light, and Oxygen 686  
 Mechanisms of Photodynamic Therapy Cytotoxicity 688  
 Clinical Indications for Photodynamic Therapy for Early Stage Cancers  
 in the Definitive Setting 689  
 Clinical Indications for Photodynamic Therapy in the Locally  
 Advanced and Palliative Settings 690  
 Molecularly Targeted Photodynamic Therapy 692

**69. Biomarkers . . . . . 694***Daniel F. Hayes*

- What is a Biomarker Used for? 694  
 What are the Criteria to Incorporate a Tumor Marker into  
 Clinical Practice? 695  
 Prognosis Versus Prediction 698  
 Pharmacogenomics: A Special Circumstance 698  
 Markers that are Accepted for Routine Clinical Utility 700

**PART EIGHT****PRACTICE OF ONCOLOGY****70. Design and Analysis of Clinical Trials . . . . 704***Richard Simon*

- Phase 1 Clinical Trials 704  
 Phase 2 Clinical Trials 706  
 Design of Phase 3 Clinical Trials 711  
 Factorial Designs 713  
 Analysis of Phase 3 Clinical Trials 716  
 Reporting Results of Clinical Trials 719  
 False-Positive Reports in the Literature 720  
 Meta-Analysis 720

**Section 1: Cancer of the Head and Neck****71. Molecular Biology of Head and  
Neck Cancers . . . . . 723***Nishant Agrawal, Joseph Califano, and  
Patrick Ha*

- Genetic Susceptibility 723  
 Molecular Networks Altered in HNSCC 724  
 Epigenetics 727  
 Loss of Heterozygosity and Risk of Malignant Progression 727

**72. Treatment of Head and Neck Cancer . . . . 729***William M. Mendenhall, John W. Werning, and  
David G. Pfister*

- Epidemiology of Head and Neck Cancer 729  
 Anatomy 729  
 Pathology 729  
 Natural History of Squamous Cell Carcinoma 729  
 Diagnostic Evaluation 730  
 Staging 731  
 Principles of Treatment for Squamous Cell Carcinoma 731  
 Management 731  
 NECK 732  
 Chemotherapy 734  
 General Principles of Combining Modalities 738  
 Chemotherapy as Part of Curative Treatment 738  
 Follow-Up 744  
 ORAL CAVITY 744  
 Lip 744  
 Floor of the Mouth 745  
 Oral Tongue 747  
 Buccal Mucosa 749  
 Gingiva and Hard Palate (Including Retromolar  
 Trigone) 750  
 OROPHARYNX 752  
 Anatomy 752  
 LARYNX 756  
 Anatomy 756  
 Pathology 756  
 Hypopharynx: Pharyngeal Walls, Pyriform Sinus, and  
 Postcricoid Pharynx 761  
 NASOPHARYNX 764  
 Anatomy 764  
 Pathology 764  
 Patterns of Spread 765  
 Clinical Picture 765  
 Staging 765  
 Treatment 766  
 Nasal Vestibule, Nasal Cavity, and Paranasal Sinuses 766  
 Paragangliomas 772  
 Major Salivary Glands 774  
 Minor Salivary Glands 777

- 84. Cancer of the Liver . . . . . 997**  
*David L. Bartlett, Adrian M. Di Bisceglie, and Laura A. Dawson*  
 Epidemiology 997  
 Etiologic Factors 997  
 Pathology 1001  
 Staging 1002  
 Clinical Features 1002  
 Clinical Evaluation 1004  
 Clinical Management 1008  
 Adjuvant Therapy 1012  
 Treatment of Other Primary Liver Tumors 1016
- 85. Cancer of the Biliary Tree . . . . . 1019**  
*David L. Bartlett, Ramesh K. Ramanathan, and Edgar Ben-Josef*  
 Cholangiocarcinomas 1019  
 Tumors of the Gallbladder 1035
- 86. Cancer of the Small Intestine . . . . . 1048**  
*Amer H. Zureikat, Matthew T. Heller, and Herbert J Zeb, III*  
 Small Bowel Cancer 1048  
 Adenocarcinoma 1052  
 Carcinoid Tumors 1053  
 Intestinal Lymphoma 1055  
 Gastrointestinal Stromal Tumors 1056  
 Other Mesenchymal Tumors 1057
- 87. Gastrointestinal Stromal Tumor . . . . . 1060**  
*George D. Demetri*  
 GIST as a Unique Clinicopathologic Subset of Sarcoma 1060  
 GIST Cells are Related to the Mesenchymal Precursor Cells that Give Rise to Normal Interstitial Cells of Cajal: Aberrant Developmental Biology 1061  
 The Development of a Molecular Understanding of GIST 1061  
 Clinical Considerations 1062  
 Prognostic Features of Gastrointestinal Stromal Tumor 1064  
 Diagnostic Imaging of Patients with Gastrointestinal Stromal Tumors 1064  
 Treatment Options and Management Decisions in the Era of Molecularly Targeted Therapies for GIST 1065  
 Extrapolation of Emerging Management Paradigms to Early-Stage GIST 1070  
 Adjuvant Therapy to Improve Outcomes for Patients with Resected Early-Stage GIST 1070  
 Special Considerations in GIST 1071  
 New Challenges and Alternative Approaches 1071
- 88. Molecular Biology of Colorectal Cancer . 1074**  
*Ramesh A. Shivdasani*  
 The Adenoma–Carcinoma Sequence and Multistep Models of Colorectal Tumorigenesis 1074  
 Early Events and Critical Pathways in Colorectal Tumorigenesis Highlighted by Inherited Syndromes of Increased Cancer Risk 1075  
 Oncogene and Tumor Suppressor Gene Mutations in Colorectal Cancer Progression 1079  
 Infrequent Changes and Current Views of the Mutational Landscape of Colorectal Cancer 1082
- 89. Cancer of the Colon . . . . . 1084**  
*Steven K. Libutti, Leonard B. Saltz, and Christopher G. Willett*  
 Epidemiology 1084  
 Etiology: Genetic and Environmental Risk Factors 1085  
 Familial Colorectal Cancer 1086  
 Anatomy of the Colon 1088  
 Diagnosis of Colorectal Cancer 1089  
 Screening for Colorectal Cancer 1089  
 Staging and Prognosis of Colorectal Cancer 1090
- Approaches to Surgical Resection of Colon Cancer 1096  
 Surgical Management of Complications from Primary Colon Cancer 1098  
 Polyps and Stage I Colon Cancer 1099  
 Stage II and Stage III Colon Cancer 1099  
 Treatment of Stage II Patients 1102  
 Treatment Options for Stage III Patients 1104  
 Radiation Therapy of Colon Cancer 1104  
 Follow-Up After Management of Colon Cancer with Curative Intent 1106  
 Surgical Management of Stage IV Disease 1108  
 Management of Unresectable Metastatic Disease 1108  
 Gene Therapy 1123  
 Molecular Predictive Markers 1123  
 Management of Synchronous Primary and Metastatic Disease 1123  
 Unusual Colorectal Tumors 1124
- 90. Cancer of the Rectum . . . . . 1127**  
*Steven K. Libutti, Christopher G. Willett, and Leonard B. Saltz*  
 Anatomy 1127  
 Staging 1128  
 Surgery 1130  
 Does Adjuvant Radiation Therapy Impact Survival? 1134  
 Preoperative Radiation Therapy 1135  
 Which Patients Should Receive Adjuvant Therapy? 1136  
 Concurrent Chemotherapy 1137  
 Synchronous Rectal Primary and Metastases 1138  
 Management of Unresectable Primary and Locally Advanced Disease (T4) 1138  
 Radiation Therapy Technique 1139
- 91. Cancer of the Anal Region . . . . . 1142**  
*Yixing Jiang, David J. Beddy, Heidi Nelson, Lisa A. Kachnic, and Jaffer A. Ajani*  
 Epidemiology and Etiology 1142  
 Pathology 1143  
 Clinical Presentation and Staging 1144  
 Prognostic Factors 1144  
 Treatment of Localized Squamous Cell Carcinoma of the Anal Canal 1145  
 Treatment of Other Sites and Pathologies 1151
- 
- Section 4: Cancers of the Genitourinary System**
- 92. Molecular Biology of Kidney Cancer . . . . 1154**  
*W. Marston Linehan and Laura S. Schmidt*  
 Von Hippel-Lindau 1154  
 Hereditary Papillary Renal Carcinoma Type 1 1155  
 XP11.2 Translocation Renal Cell Cancer 1156  
 Birt-Hogg-Dubé Syndrome 1156  
 Hereditary Leiomyomatosis and Renal Cell Carcinoma 1157  
 Familial Renal Cancer: Succinate Dehydrogenase Gene 1158  
 Tuberous Sclerosis Complex 1159  
 Conclusion 1159
- 93. Cancer of the Kidney . . . . . 1161**  
*W. Marston Linehan, Brian I. Rini, and James C. Yang*  
 Histologic Types of Renal Carcinoma 1161  
 Hereditary Forms of Kidney Cancer 1161  
 Transcription Factors and Kidney Cancer 1164  
 Localized Renal Carcinoma 1169  
 Metastatic Renal Carcinoma 1170
- 94. Molecular Biology of Bladder Cancer . . . 1183**  
*Margaret A. Knowles*  
 Molecular Alterations in Superficial Urothelial Carcinoma 1183  
 Carcinoma in Situ 1186  
 Molecular Alterations in Invasive Urothelial Carcinoma 1186

## 73. Rehabilitation after Treatment of Head and Neck Cancer. . . . . 781

*Douglas B. Chepeha, Mark J. Haxer, and Teresa H. Lyden*

- Pretreatment Counseling 781
- Support During Treatment and Rehabilitation of the Chemoradiation Patient 781
- Resources for Rehabilitation of Head and Neck Cancer Patients 787

## Section 2: Cancer of the Thoracic Cavity

## 74. Molecular Biology of Lung Cancer . . . . . 789

*Jacob Kaufman, Leora Horn, and David Carbone*

- Susceptibility to Lung Cancer: Genetic Susceptibility and Carcinogens in Tobacco Smoke 789
- Molecular Changes in Preneoplasia 789
- Genetic and Epigenetic Alterations in Lung Cancers 791
- Protooncogenes, Growth Factor Signaling, and Growth Factor Targeted Therapies 791
- Tumor Suppressor Genes and Growth Suppression 793
- Cyclins and Cell Cycle Regulatory Pathways 794
- Other Biologic Abnormalities in Lung Cancer 795
- Cancer Stem Cell Hypothesis 796
- Genomic Analysis of Lung Cancer 797
- Molecular Tools in the Lung Cancer Clinic 797

## 75. Non-Small Cell Lung Cancer. . . . . 799

*David S. Schrupp, Darryl Carter, Christopher R. Kelsey, Laurence B. Marks, and Giuseppe Giaccone*

- Incidence 799
- Etiology 799
- Pathology 802
- Molecular Markers of Prognosis 805
- Modes of Metastasis 806
- Clinical Manifestations 806
- Staging and Diagnosis 807
- Methods to Establish Tissue Diagnosis 811
- Overview of Invasive Lung Cancer Management: Treatment Modalities 813
- Specifics of Lung Cancer Management 820
- Superior Sulcus Tumors 829
- Unresectable or Medically Inoperable 829
- Locally Advanced 830
- Advanced Disease 833
- Investigational Agents in Development for NSCLC 843
- Personalized Medicine in NSCLC 843
- Local Therapies and Palliation 844

## 76. Small Cell and Neuroendocrine Tumors of the Lung. . . . . 848

*Lee M. Krug, M. Catherine Pietanza, Mark G. Kris, Kenneth Rosenzweig, and William D. Travis*

- Small Cell Lung Cancer 848
- Typical Carcinoid and Atypical Carcinoid Tumors 863
- Large Cell Neuroendocrine Carcinoma 867

## 77. Neoplasms of the Mediastinum . . . . . 871

*Robert B. Cameron, Patrick J. Loehrer, and Charles R. Thomas, Jr.*

- Thymic Neoplasms 871
- Thymoma 871
- Thymic Carcinoma 872
- Thymic Carcinoid 878
- Thymolipoma 878
- Germ Cell Tumors 878

## Section 3: Cancers of the Gastrointestinal Tract

## 78. Molecular Biology of the Esophagus and Stomach. . . . . 882

*Anil K. Rustgi*

- Molecular Biology of Esophageal Cancer 882
- Molecular Biology of Gastric Cancer 884

## 79. Cancer of the Esophagus . . . . . 887

*Mitchell C. Posner, Bruce D. Minsky, and David H. Ilson*

- Epidemiology 887
- Etiologic Factors and Predisposing Conditions 887
- Applied Anatomy and Histology 891
- Natural History and Patterns of Failure 892
- Clinical Presentation 892
- Diagnostic Studies and Pretreatment Staging 893
- Pathologic Staging 894
- Treatment 895
- Stage-Directed Treatment Recommendations 921

## 80. Cancer of the Stomach. . . . . 924

*Itzhak Avital, Peter W.T. Pisters, David P. Kelsen, and Christopher G. Willett*

- Epidemiology and Etiology 924
- Anatomic Considerations 926
- Pathology and Tumor Biology 927
- Histopathology 927
- Patterns of Spread 927
- Clinical Presentation and Pretreatment Evaluation 928
- Pretreatment Staging 929
- Staging, Classification, and Prognosis 930
- Gastric Cancer Nomograms: Predicting Individual Patient Prognosis After Potentially Curative Resection 933
- Treatment of Localized Disease 934
- Technical Treatment-Related Issues 944
- Treatment of Advanced Disease (Stage IV) 945
- Surgery in Treatment of Metastatic Gastric Cancer 952
- Radiation for Palliation 952

## 81. Molecular Biology of Pancreas Cancer. . . . . 955

*Scott E. Kern and Ralph H. Hruban*

- Common Molecular Changes 955
- Low-Frequency Genetic Changes 958

## 82. Cancer of the Pancreas. . . . . 961

*Richard E. Royal, Robert A. Wolff, and Christopher H. Crane*

- Incidence and Etiology 961
- Anatomy and Pathology 964
- Screening 964
- Diagnosis and Staging 965
- Staging 967
- Treatment of Potentially Resectable Disease: American Joint Committee on Cancer Stage I and II 967
- Treatment of Locally Advanced Disease: American Joint Committee on Cancer Stage III 975
- Treatment of Metastatic Disease: American Joint Committee on Cancer Stage IV 980
- Other Exocrine Neoplasms 986

## 83. Molecular Biology of Liver Cancer . . . . . 990

*Snorri S. Thorgeirsson and Joe W. Grisham*

- Allelic Imbalance in Liver Cancer 990
- Classification and Prognostic Prediction of Hepatocellular Carcinoma 991
- Comparative Functional Genomics 995
- Conclusion and Perspective 995

t(1;22) Translocation Associated with Infant Acute Megakaryoblastic Leukemia	1921
Deletions and Numeric Abnormalities in Acute Leukemias	1921
Chromosomal Translocations that Result in Overexpression of Otherwise Normal Genes	1922
Chromosomal Translocations Involving the T-Cell Receptor	1922
Point Mutations in Acute Leukemia	1922
Mutation in Tumor Suppressor Genes	1924
Activating Mutations of NOTCH	1924
Mutations Altering Localization of NPM1	1925
Loss-of-Function Point Mutations in <i>AML1</i> , <i>C/EBP<math>\alpha</math></i> , and <i>GATA-1</i>	1925
Mutation of Lymphoid Development Genes in ALL	1925
Mutational Complementation Groups in Acute Leukemias	1925
Conclusion	1926

### 131. Management of Acute Leukemias . . . . . 1928

*Partow Kebriaei, Richard Champlin, Marcos de Lima, and Elibu Estey*

Acute Myelogenous Leukemia	1929
Acute Lymphoblastic Leukemia	1946

### 132. Molecular Biology of Chronic Leukemias . . . . . 1955

*Anupriya Agarwal, John C. Byrd, and Michael W. Deininger*

Chronic Myeloid Leukemia	1955
Chronic Lymphocytic Leukemia	1958

### 133. Chronic Myelogenous Leukemia . . . . . 1962

*Brian J. Druker and Stephanie J. Lee*

Epidemiology	1962
Pathogenesis	1962
Diagnosis	1963
Clinical Course and Prognosis	1964
Treatment of Chronic Phase Disease	1965
Tyrosine Kinase Inhibitors	1965
Hematopoietic Cell Transplantation	1968
Advanced Phase Disease	1970
Future Directions	1971

### 134. Chronic Lymphocytic Leukemias . . . . . 1973

*William G. Wierda and Susan O'Brien*

Molecular Biology	1973
Immune Abnormalities	1975
Diagnosis	1975
Clinical Manifestations	1975
Treatment and Response Criteria	1977
New and Novel Agents for Treatment of Chronic Lymphocytic Leukemia	1984
Second Malignancies and Transformation	1985
Prolymphocytic Leukemia	1985
Large Granular Lymphocyte Leukemia	1985
Hairy Cell Leukemia	1986

### 135. Myelodysplastic Syndromes . . . . . 1988

*Stefan Faderl and Hagop M. Kantarjian*

Epidemiology and Etiology	1988
Presentation and Diagnosis	1988
Cytogenetic-Molecular Abnormalities and MDS Pathogenesis	1990
Classification	1991
Therapy	1992
Outlook	1995

### 136. Plasma Cell Neoplasms . . . . . 1997

*Nikhil C. Munshi and Kenneth C. Anderson*

History	1997
Epidemiology	1998
Etiology	1998
Pathogenesis	1999
Drug Resistance	2004
Clinical Manifestations	2005
Treatment	2015

## Section 14: Other Cancers

### 137. Cancer of Unknown Primary Site. . . . . 2033

*F. Anthony Greco and John D. Hainsworth*

Pathologic Evaluation	2033
Clinical Features and Evaluation	2038
Treatment	2040
Special Issues in Carcinoma of Unknown Primary Site	2048
Unknown Primary Cancer in Children	2049
Future Directions and Changing Treatment Paradigm	2050

### 138. Benign and Malignant Mesothelioma . . . 2052

*Harvey I. Pass, Nicholas T. Vogelzang, Steven M. Hahn, and Michele Carbone*

Mechanism of Asbestos-Carcinogenesis	2052
Overview of Molecular Mechanisms in Mesothelioma	2054
Alterations of Oncogenes in Mesothelioma	2054
Pathology of Mesothelioma	2056
Epidemiology and Clinical Presentation	2058
Diagnostic Approach for Presumed Mesothelioma	2062
Natural History	2064
Treatment	2066
Pleurectomy	2068
Radiotherapy for Mesothelioma	2069
Multimodality Treatment	2071
Novel Intrapleural Approaches: New Techniques with New/Old Agents	2072
Chemotherapy and Newer Agents	2074
Novel Treatment Approaches	2076
Other Agents	2077

### 139. Peritoneal Surface Malignancy . . . . . 2081

*Marcello Deraco, Dominique Elias, Olivier Glehen, Cyril W. Helm, Paul H. Sugarbaker, and Vic J. Vervaal*

Rationale for a Combined Treatment for Peritoneal Surface Malignancy	2081
Validated Quantitative Prognostic Indicators	2081
Appendiceal Malignancy	2083
Colorectal Carcinomatosis: Curative Treatment and Prevention	2084
Diffuse Malignant Peritoneal Mesothelioma	2085
Gastric Cancer	2086
Peritoneal Carcinomatosis in Ovarian Cancer	2087
Sarcomatosis	2087

### 140. Intraocular Melanoma . . . . . 2090

*Daniel M. Albert and Amol D. Kulkarni*

Incidence and Etiology	2090
Anatomy and Pathology	2090
Diagnosis	2091
Metastatic Workup	2093
Staging	2093
Management	2093
Prognostic and Predictive Factors	2096
Posttreatment Quality of Life	2097

## Section 15: Immunosuppression-Related Malignancies

### 141. AIDS-Related Malignancies . . . . . 2099

*Robert Yarchoan, Thomas S. Uldrick, and Richard F. Little*

Cancer and HIV: Incidence and Etiology	2099
Kaposi Sarcoma	2101
KSHV-Associated Multicentric Castleman Disease	2104
AIDS-Associated Lymphomas	2104
Hodgkin's Lymphoma	2110
HPV-Associated Cancer in HIV Infection	2110
Cervical Cancer	2110
Anal Cancer	2110
Future Directions	2111

**142. Transplantation-Related Malignancies . . . 2113***Smita Bhatia and Ravi Bhatia*

- Myelodysplasia and Acute Myeloid Leukemia 2113  
 Lymphomas 2119  
 Solid Tumors 2120

**Section 16: Oncologic Emergencies****143. Superior Vena Cava Syndrome . . . . . 2123***Joachim Yahalom*

- Anatomy and Pathophysiology 2123  
 Etiology and Natural History 2123  
 Diagnostic Procedures 2124  
 Management 2125  
 Small Cell Lung Cancer 2125  
 Non-Small Cell Lung Cancer 2125  
 Non-Hodgkin's Lymphoma 2125  
 Nonmalignant Causes 2126  
 Catheter-Induced Obstruction 2126  
 Treatment 2126  
 Areas of Uncertainty 2127  
 Recommendations 2128

**144. Increased Intracranial Pressure . . . . . 2130***Kevin P. Becker and Joachim M. Baehring*

- Pathophysiological Considerations 2130  
 Epidemiology and Pathogenesis 2131  
 Clinical Presentation 2131  
 Diagnosis 2133  
 Treatment 2134

**145. Spinal Cord Compression . . . . . 2136***Kevin P. Becker and Joachim M. Baehring*

- Epidemiology 2136  
 Pathophysiology 2136  
 Clinical Presentation 2138  
 Differential Diagnosis 2138  
 Diagnosis 2139  
 Treatment 2139  
 Prognosis 2140

**146. Metabolic Emergencies . . . . . 2142***Antonio Tito Fojo*

- Tumor Lysis Syndrome 2142  
 Hyperuricemia 2144  
 Cancer and Hyponatremia 2147  
 Lactic Acidosis and Cancer 2148  
 Hypercalcemia and Cancer 2148  
 Cancer-Related Hemolytic Uremic Syndrome 2150

**Section 17: Treatment of Metastatic Cancer****147. Metastatic Cancer to the Brain . . . . . 2153***David A. Larson, James L. Rubenstein, Michael W. McDermott, and Igor Barani*

- Brain Metastasis 2153  
 Carcinomatous Meningitis 2162

**148. Metastatic Cancer to the Lung . . . . . 2165***King F. Kwong and Robert Timmerman*

- Rationale for Local Therapies for Lung Metastases 2165  
 Modes of Metastatic Spread 2165  
 Diagnosis 2165

**149. Metastatic Cancer to the Liver . . . . . 2177***H. Richard Alexander Jr., Jordan Berlin, and Fred Moeslein*

- Natural History of Liver Metastases 2177  
 Imaging of Liver Metastases 2179  
 Resection of Liver Metastases 2179  
 Results of Hepatic Resection for CRC 2180  
 Results of Resection for Noncolorectal Cancers 2181  
 Adjuvant Therapy for Resectable CRC Liver Metastases 2181  
 Neoadjuvant Chemotherapy for CRC Liver Metastases 2183  
 Regional Therapies for Unresectable Isolated Liver Metastases 2184  
 Radiation Therapy for Liver Metastases 2188  
 Conclusions 2190

**150. Metastatic Cancer to the Bone . . . . . 2192***Edward Chow, Joel A. Finkelstein, Arjun Sahgal, and Robert E. Coleman*

- Presentation 2192  
 Pathophysiology 2192  
 Diagnostic Evaluation 2192  
 Therapeutic Modalities 2193  
 New Targeted Therapies in the Treatment of Metastatic Bone Disease 2194  
 External-Beam Radiation Therapy 2195  
 Systemic Radionuclides 2197  
 Radiotherapy for Complications of Bone Metastases: Localized External Beam Radiotherapy for Pathological Fractures and Spinal Cord Compression 2198  
 Mechanical Stability and Fracture Risk 2199

**151. Malignant Effusions of the Pleura and the Pericardium . . . . . 2205***King F. Kwong and Dao M. Nguyen*

- Malignant Pleural Effusion 2205  
 Malignant Pericardial Effusion 2209

**152. Malignant Ascites . . . . . 2214***Udai S. Kammula*

- Pathophysiology 2214  
 Diagnosis and Workup 2215  
 Treatment of Malignant Ascites 2216

**153. Paraneoplastic Syndromes . . . . . 2220***Michael Boyiadzis, Frank S. Lieberman, Larisa J. Geskin, and Kenneth A. Foon*

- Endocrinologic Manifestations of Cancer 2220  
 Hematologic Manifestations of Cancer 2222  
 Renal Manifestations 2223  
 Cutaneous Manifestations of Cancer 2224  
 Disorders of Epidermal Proliferation and Keratinization (Papulosquamous Disorders) 2224  
 Disorders of Cutaneous Discoloration and Deposition 2225  
 Neutrophilic Dermatoses 2226  
 Vascular Abnormalities 2226  
 Endocrine and Metabolic Disorders 2226  
 Bullous Disorders 2226  
 Collagen-Vascular Diseases 2227  
 Disorders of Hair 2227  
 Skin Neoplasms Associated with Internal Malignancy 2227  
 Miscellaneous Lesions 2229  
 Neurologic Manifestations of Cancer 2229  
 Limbic Encephalitis 2229  
 Autonomic Neuropathy 2231  
 Progressive Cerebellar Degeneration 2231  
 Paraneoplastic Visual Loss 2231  
 Opsoclonus-Myoclonus 2232  
 Paraneoplastic Motor Neuron Disorders 2232  
 Paraneoplastic Peripheral Neuropathies 2233  
 Neuromuscular Junction Disorders 2233

## PART FIVE

## CANCER PREVENTION

- 50. Preventive Cancer Vaccines. . . . . 522**  
*Douglas R. Lowy and John T. Schiller*
- Background 522  
 Infectious Agents and Cancer 522  
 Prophylactic Versus Therapeutic Vaccination 524  
 Hepatitis B Virus 524  
 Human Papillomavirus 525  
*Helicobacter Pylori* 527
- 51. Tobacco Dependence and Its Treatment. . . . . 529**  
*Ellen R. Gritz, Cho Y. Lam, Damon J. Vidrine, and Michelle Cororve Fingeret*
- Nicotine and the Neurobiological Basis of Smoking 529  
 Smoking Prevalence and Quit Rates 529  
 Effects of Continued Smoking on Cancer Treatment Outcomes 530  
 Cessation Treatment and Research 532  
 Future Research and Clinical Opportunities 540
- 52. Role of Surgery in Cancer Prevention. . . . . 543**  
*José G. Guillem, Andrew Berchuck, Jeffrey F. Moley, Jeffrey Norton, and Sheryl G. A. Gabram*
- Patients at High Risk for Breast Cancer 543  
 Hereditary Diffuse Gastric Cancer 545  
 Surgical Prophylaxis of Hereditary Ovarian and Endometrial Cancer 547  
 Hereditary Endometrial Cancer (Lynch Syndrome) 548  
 Multiple Endocrine Neoplasia Type 2 549  
 Familial Adenomatous Polyposis, MYH-Associated Polyposis, and Lynch Syndrome 552
- 53. Principles of Cancer Risk Reduction Intervention . . . . . 558**  
*Dean E. Brenner*
- Why Cancer Prevention as a Clinical Oncology Discipline? 558  
 Defining Cancer Risk Reductive Intervention (Chemoprevention) 558  
 Identifying Potential Cancer Risk Reductive Interventions 558  
 Preclinical Development of Cancer Risk Reductive Interventions 559  
 Clinical Development of Cancer Risk Reductive Interventions 561  
 Implementation of Cancer Risk Reductive Interventions in the Community 562
- 54. Retinoids, Carotenoids, and Other Micronutrients in Cancer Prevention . . . . . 564**  
*Susan T. Mayne, Edward Giovannucci, and Scott M. Lippman*
- Head and Neck Cancer Chemoprevention 564  
 Lung Cancer Chemoprevention 565  
 Breast Cancer Chemoprevention 567  
 Skin Cancer Chemoprevention 567  
 Bladder Cancer Chemoprevention 568  
 Cervical Cancer Chemoprevention 568  
 Esophageal/Gastric Cancer Chemoprevention 569  
 Colorectal Cancer Chemoprevention 569  
 Prostate Cancer Chemoprevention 570  
 Conclusions 571
- 55. Drugs and Nutritional Extracts for Cancer Risk Reduction (Chemoprevention). . . . . 573**  
*Madhuri Kakarala and Dean E. Brenner*
- Anti-Inflammatory Drugs 573  
 Signal Transduction Modifiers 578  
 Anti-Infectives 579

## PART SIX

## CANCER SCREENING

- 56. Principles of Cancer Screening . . . . . 582**  
*Jack S. Mandel and Robert Smith*
- Principles of Screening 582  
 Evaluating Screening Tests 583  
 Developing and Evaluating a Cancer Screening Program 585
- 57. Early Detection Using Proteomics . . . . . 587**  
*Virginia Espina, Claudio Belluco, Emanuel F. Petricoin III, and Lance A. Liotta*
- Cellular Proteomics 587  
 Biomarker Proteomics 592
- 58. Screening for Gastrointestinal Cancers. . . . . 596**  
*Timothy R. Church and Jack S. Mandel*
- History of Colorectal Cancer Screening 596  
 Polyp Removal and Colorectal Cancer Prevention 597  
 Methods of Screening for Colorectal Cancer 597  
 Colorectal Cancer Screening for High-Risk Patients 600  
 Other Gastrointestinal Cancers 600  
 Screening 601
- 59. Screening for Gynecologic Cancers . . . . . 603**  
*Mary B. Daly and Janet S. Rader*
- Cervical Cancer 603  
 Ovarian Cancer 606  
 Endometrial Cancer 607
- 60. Screening for Breast Cancer . . . . . 610**  
*Laura J. Esserman and Chris I. Flowers*
- The Evidence of Mortality Benefit from Randomized Trials of Mammography Screening 610  
 Changes in Systemic Therapies and Impact on Screening 610  
 Optimizing the Organization of Screening 611  
 Optimizing the Interpretation of Mammography 611  
 Addressing the Potential Harms and Limitations of Screening 612  
 High-Risk Screening 614  
 What has Biology Taught Us? 614  
 Conclusion and Considerations for Screening 615
- 61. Screening for Prostate Cancer . . . . . 617**  
*Peter C. Albertsen*
- Is Prostate Cancer a Suitable Disease for Screening? 617  
 Is Treatment for Prostate Cancer Effective? 618  
 Is Prostate-Specific Antigen an Effective Screening Test? 620  
 Recent Evidence from Randomized Trials 621  
 Are there Substantial Risks Associated with Prostate-Specific Antigen Screening? 622  
 How Should Physicians Advise their Patients? 622
- 62. Screening for Lung Cancer. . . . . 625**  
*David E. Midthun and James R. Jett*
- The Opportunity 625  
 Chest Radiography and Sputum Cytology 625  
 CT Screening 626  
 The Problems with CT Screening 627  
 Other Methods of Screening 629  
 Future Directions 629

Gemcitabine 397  
 6-Thiopurines 398  
 Fludarabine 399  
 Cladribine 399  
 Clofarabine 400

### 37. Topoisomerase-Interacting Agents . . . . . 402

*Zeshaan A. Rasheed and Eric H. Rubin*

Topoisomerase Biology 402  
 Camptothecins 402  
 Anthracyclines 404  
 Anthracenediones 409  
 Epipodophyllotoxins 410

### 38. Antimicrotubule Agents . . . . . 413

*Maysa M. Abu-Khalaf and Lyndsay N. Harris*

Microtubules 413  
 Taxanes 413  
 New Taxane Formulations 416  
 Vinca Alkaloids 417  
 Estramustine Phosphate 420  
 Epopthilones 420  
 Novel Compounds Targeting Microtubules and  
 Mitotic Motor Proteins 420

### 39. Targeted Therapy with Small Molecule Kinase Inhibitors . . . . . 422

*Charles L. Sawyers*

Early Successes: Targeting Cancers with Well-Known Kinase  
 Mutations 422  
 Targeting the PI3K Pathway Directly 431  
 Combinations of Kinase Inhibitors 431  
 Speculations on the Future Role of Kinase Inhibitors in  
 Cancer Medicine 432

### 40. Histone Deacetylase Inhibitors and Demethylating Agents . . . . . 434

*Steven D. Gore, Stephen B. Baylin, and James G. Herman*

Epigenetics and Gene Silencing 434  
 Changes in DNA Methylation 434  
 Histone Deacetylase Inhibitors 437  
 Pharmacodynamic Observations 439

### 41. Proteasome Inhibitors . . . . . 441

*Michael G. Kauffman, Christopher J. Molineaux,  
 Christopher J. Kirk, and Craig M. Crews*

Biochemistry of the Ubiquitin-Proteasome Pathway 441  
 Proteasome Inhibitors 441  
 Preclinical Pharmacology of PIs 445  
 Proteasome Inhibitors in Cancer 445

### 42. Poly(ADP-Ribose) Polymerase Inhibitors . . . . . 450

*Alan Ashworth*

Cellular DNA Repair Pathways 450  
 The Development of PARP Inhibitors 450  
 BRCA1 and BRCA2 Mutations and DNA Repair 451  
 PARP1 Inhibition as a Synthetic Lethal Therapeutic Strategy for the  
 Treatment of BRCA-Deficient Cancers 451  
 Mechanisms of Resistance to PARP Inhibitors 452  
 Initial Clinical Results Testing Synthetic Lethality 452  
 The Use of PARP Inhibitors in Sporadic Cancers  
 with "BRCAness" 452  
 Prospects 453

### 43. Miscellaneous Chemotherapeutic Agents . . . 455

*M. Sitki Copur, Michal Rose, and Scott Gettinger*

Sirolimus and Temsirolimus 455  
 Everolimus 455

L-Asparaginase 456  
 Bleomycin 456  
 Procarbazine 457  
 Thalidomide 458  
 Lenalidomide 458

## Section 2: Biotherapeutics

### 44. Interferons . . . . . 461

*Vernon K. Sondak, Jürgen C. Becker, and Axel Hauschild*

Interferon Signaling Pathways 461  
 Immunologic Effects of Interferon 463  
 Nonimmunologic Antiangiogenic Effects of Interferon 464  
 Direct Antitumor Effects of Interferons 464  
 Clinical Toxicity of Interferon Administration 464  
 Potential Drug Interactions 466  
 Oncologic Applications of Interferons 466

### 45. Interleukin Therapy . . . . . 469

*Michael T. Lotze*

Interleukins as Therapeutics 469  
 Interleukin-1 Family 469  
 Interleukin 3, Interleukin 11, and Interleukin 34 470  
 Interleukin-2 Family 470  
 Interleukin 6 Family 477  
 Interleukin 10 Family 480

### 46. Antisense Agents . . . . . 482

*Cy A. Stein and Harris S. Soifer*

Oligonucleotide Stability and Efficacy: The Role of  
 Phosphorothioates 482  
 Clinical Trials of G3139 (Oblimersen) in Chronic Lymphocytic  
 Leukemia 483  
 Clinical Trials in Advanced Melanoma 484

### 47. Antiangiogenesis Agents . . . . . 489

*Cindy H. Chau and William D. Figg*

Understanding the Angiogenic Process 489  
 Drug Development of Angiogenesis Inhibitors 490  
 Clinical Utility of Approved Antiangiogenic Agents in  
 Cancer Therapy 494  
 Combination Therapies 496  
 Surrogate Markers of Antiangiogenic Therapy 497  
 Resistance to Antiangiogenic Therapy 497

### 48. Monoclonal Antibodies . . . . . 499

*Matthew K. Robinson, Hossein Borghaei, Gregory P. Adams,  
 and Louis M. Weiner*

Immunoglobulin Structure 499  
 Modified Antibody-Based Molecules 499  
 Factors Regulating Antibody-Based Tumor Targeting 500  
 Unconjugated Antibodies 502  
 Altering Signal Transduction 503  
 Immunoconjugates 504  
 Unconjugated Antibodies Approved for Use Against Solid  
 Tumors 505  
 Antibodies Used in Hematologic Malignancies 506

### 49. Endocrine Manipulation . . . . . 508

*Matthew P. Goetz, Charles Erlichman, Manish Kohli, and  
 Charles L. Loprinzi*

Selective Estrogen Receptor Modulators 508  
 Aromatase Inhibitors 513  
 Gonadotropin-Releasing Hormone Analogues 514  
 Gonadotropin-Releasing Hormone Antagonists 515  
 Antiandrogens 515  
 Novel Antiandrogens 516  
 Other Sex Steroid Therapies 516  
 Other Hormonal Therapies 518

**24. Trends in Cancer Mortality . . . . . 261***Tim E. Byers*

- Cancer Surveillance Systems 261
- Making Sense of Cancer Trends 261
- Trends in Cancer Risk Factors 261
- Cancer Trends 263
- Predicting Future Cancer Trends 265

**PART THREE****PRINCIPLES OF CANCER TREATMENT****25. Surgical Oncology: General Issues . . . . . 268***Steven A. Rosenberg*

- Historical Perspective 268
- Anesthesia for Oncologic Surgery 268
- Determination of Operative Risk 270
- Roles for Surgery 272
- Surgical Oncologist 274

**26. Surgical Oncology: Laparoscopic Surgery . . . . . 277***Yoshinori Hosoya and Alan T. Lefor*

- New Technology 277
- Physiology of Laparoscopy 278
- Laparoscopy in the Diagnosis of Malignancy 279
- Laparoscopy in the Staging of Malignancy 279
- Laparoscopy in the Treatment of Malignancy 281
- Laparoscopy in the Palliation of Malignancy 287

**27. Radiation Oncology . . . . . 289***Meredith A. Morgan, Randall K. Ten Haken, and Theodore S. Lawrence*

- Biologic Aspects of Radiation Oncology 289
- Factors that Affect Radiation Response 294
- Drugs that Affect Radiation Sensitivity 296
- Radiation Physics 297
- Treatment Planning 301
- Other Treatment Modalities 303
- Clinical Applications of Radiation Therapy 304
- Treatment Intent 305
- Fractionation 306
- Adverse Effects 307
- Principles of Combining Anticancer Agents with Radiation Therapy 308

**28. Medical Oncology . . . . . 312***Vincent T. DeVita, Jr. and Edward Chu*

- Introduction 312
- Biology of Drug Resistance 316

**29. Assessment of Clinical Response . . . . . 322***Antonio Tito Fojo and Susan Elaine Bates*

- Overall Response Rate and Stable Disease 322
- Alternate Response Criteria 323
- Waterfall Plots 326
- Progression Free Survival and Time to Progression 326
- Overall Survival 327
- Kaplan-Meier Plots 328
- Hazard Ratios 329
- Forest Plots 329
- Meta-Analyses 329
- Quality of Life 329
- Novel End Points 329

**30. Cancer Immunotherapy . . . . . 332***Steven A. Rosenberg, Paul F. Robbins, and Nicholas P. Restifo*

- Approaches to the Identification of Human Tumor Antigens 332

- Categories of Tumor Antigens Can Be Defined by Expression Patterns 334
- Cancer Immunotherapies 337

**31. Health Services Research and Economics of Cancer Care . . . . . 345***Craig C. Earle and Deborah Schrag*

- Studies of Health Service Delivery in Cancer Medicine 345
- Patient-Reported Outcomes Assessment 350
- The Economics of Cancer Care 353
- Comparative Effectiveness Research 356

**PART FOUR****PHARMACOLOGY OF CANCER THERAPEUTICS****Section 1: Chemotherapy Agents****32. Pharmacokinetics and Pharmacodynamics . . . . . 360***Chris H. Takimoto, Chee M. Ng, and Thomas Puchalski*

- Why Study Pharmacokinetics and Pharmacodynamics? 360
- Cancer Patients Present Unique Challenges 361
- Pharmacokinetic Concepts 361
- Pharmacodynamic Concepts 365
- Special Topics in Pharmacokinetics and Pharmacodynamics 365
- Population Pharmacokinetics/Pharmacodynamics 366
- Pharmacokinetics and Pharmacodynamics in Oncology Drug Development 366

**33. Pharmacogenomics . . . . . 369***Anthony El-Khoueiry and Heinz Josef Lenz*

- Definitions: Terms and Concepts 369
- Pharmacogenomics and Predictive Molecular Markers 369
- Pharmacogenomics and Prognostic Markers 372
- Current Challenges and Future Directions 373

**34. Alkylating Agents . . . . . 375***Kenneth D. Tew*

- Perspectives 375
- Chemistry 375
- Classification 375
- Clinical Pharmacokinetics/Pharmacodynamics 380
- Therapeutic Uses 381
- Toxicities 381
- Complications with High-Dose Alkylating Agent Therapy 383
- Alkylating Agent–Steroid Conjugates 383
- Drug Resistance and Modulation 383
- Recent Developments 383

**35. Platinum Analogs . . . . . 386***Eddie Reed*

- Common Features of Platinum Chemistry 387
- Clinical Pharmacology 388
- Determinants of Cellular Sensitivity and Resistance to Platinum Agents 389
- Cellular Accumulation and Cytosolic Inactivation of Drug 390
- DNA Damage and Repair 390

**36. Antimetabolites . . . . . 393***M. Wasif Saif and Edward Chu*

- Antifolates 393
- 5-Fluoropyrimidines 396
- Capecitabine 396
- Cytarabine 397

- Cancer Stem Cells in Solid Tumors 130  
 Genetic Diversity and Clonal Evolution in Cancer 133  
 The Origins of Cancer Stem Cells 134  
 Epithelial-Mesenchymal Transition 137  
 Cancer Stem Cells: Targeted Therapy 137

## 12. Biology of Personalized Cancer Medicine . . . 141

*Raju Kucherlapati*

- Cancer Predisposition 141  
 Familial Adenomatous Polyposis 141  
 Lynch Syndrome 142  
 Other Polyposis Syndromes 142  
 Association Studies 142  
 Breast Cancer 142  
 Early Detection 143  
 Tumor Classification and Patient Stratification 143  
 Treatment 144  
 Development of Resistance to Tyrosine Kinase Inhibitors 145  
 Alternative Mechanisms of Resistance 145  
 BRAF Inhibitors 146  
 The Future 146  
 Changing Face of Personalized Medicine 146  
 Summary 146

## PART TWO

### ETIOLOGY AND EPIDEMIOLOGY OF CANCER

#### Section 1: Etiology of Cancer

## 13. Tobacco . . . . . 150

*Stephen S. Hecht*

- Epidemiology of Tobacco and Cancer 150  
 Tumor Induction in Laboratory Animals by Tobacco Products 152  
 Carcinogens in Tobacco Products 153  
 Overview of Mechanisms of Tumor Induction by Tobacco Products 156  
 Tobacco Carcinogen and Toxicant Biomarkers 157

## 14. Cancer Susceptibility Syndromes . . . . . 161

*Alice Hawley Berger and Pier Paolo Pandolfi*

- Principles of Cancer Susceptibility 161  
 Genetic Testing 163  
 Cancer Susceptibility Syndromes 164  
 Future Directions 170

## 15. DNA Viruses . . . . . 173

*Peter M. Howley, Don Ganem, and Elliott Kieff*

- History of Viral Oncology 173  
 Hepadnaviruses and Hepatocellular Carcinoma 174  
 Papillomaviruses 176  
 Epstein-Barr Virus 180  
 Kaposi's Sarcoma-Associated Herpesvirus 182  
 Human Polyomaviruses 184

## 16. RNA Viruses . . . . . 186

*Gary L. Buchsacher, Jr. and Flossie Wong-Staal*

- Retroviruses: Background, Replication Cycle, and  
 Molecular Genetics 186  
 Human T-Lymphotropic Virus Type 1 189  
 Human T-Lymphotropic Virus Type 2 190  
 Human Immunodeficiency Virus 190  
 Hepatitis C Virus 190

## 17. Inflammation . . . . . 193

*Giorgio Trinchieri*

- Tumor Immune Surveillance 193  
 Inflammation and Tumorigenesis 194

- Mechanisms of Cell Transformation and Cancer Initiation in the  
 Inflammatory Environment 196  
 Inflammatory Cells and Stromal Cells in the Initiation of Neoplasia  
 and in the Tumor Microenvironment 198

## 18. Chemical Factors . . . . . 203

*Stuart H. Yuspa and Peter G. Shields*

- The Nature of Chemical Carcinogens: Chemistry  
 and Metabolism 203  
 Animal Model Systems and Chemical Carcinogenesis 205  
 DNA Repair Protects the Host from Chemical  
 Carcinogens 205  
 Genetic Susceptibility to Chemical Carcinogenesis 205  
 Molecular Epidemiology, Chemical Carcinogenesis, and  
 Cancer Risk in Human Populations 206  
 Polycyclic Aromatic Hydrocarbons as a Model for Gene-Environment  
 Interaction 207

## 19. Physical Factors . . . . . 209

*Mats Ljungman*

- Ionizing Radiation 209  
 Ultraviolet Light 212  
 Radiofrequency and Microwave Radiation 214  
 Electromagnetic Fields 214  
 Asbestos 214  
 Nanoparticles 215

## 20. Dietary Factors . . . . . 217

*Karin B. Michels and Walter C. Willett*

- Methodologic Challenges 217  
 The Role of Individual Food and Nutrients in  
 Cancer Etiology 218  
 Other Foods and Nutrients 222  
 Dietary Patterns 224  
 Diet During Early Phases of Life 224  
 Summary 224  
 Limitations 224  
 Future Directions 225  
 Recommendations 225

## 21. Obesity and Physical Activity . . . . . 227

*Katherine D. Henderson, Yani Lu, and Leslie Bernstein*

- Breast Cancer 227  
 Colon and Rectal Cancer 228  
 Endometrial Cancer 229  
 Adenocarcinoma of the Esophagus 229  
 Kidney/Renal Cell Cancer 230  
 Pancreatic Cancer 230  
 Gallbladder Cancer 230  
 Non-Hodgkin Lymphoma 230  
 Prostate Cancer 231  
 Lung Cancer 231  
 Ovarian Cancer 231  
 Overview 231

#### Section 2: Epidemiology of Cancer

## 22. Epidemiologic Methods . . . . . 233

*Xiaomei Ma and Herbert Yu*

- Analytical Studies 233  
 Interpretation of Epidemiologic Findings 236  
 Molecular Epidemiology 237

## 23. Global Cancer Incidence and Mortality . . . 241

*Michael J. Thun, Ahmedin Jemal, and Elizabeth Ward*

- Data Sources and Measurements 241  
 Overall Cancer Risk 243  
 Incidence and Mortality Patterns for Common Cancers 251  
 Issues in Interpreting Temporal Trends 258  
 Conclusion 259

Contributing Authors *vii*  
 Preface *xxvii*  
 Acknowledgments *xxix*

## PART ONE

### MOLECULAR BIOLOGY OF CANCER

- 1. The Cancer Genome . . . . . 2**  
*Yardena Samuels, Alberto Bardelli, and Carlos López-Otín*  
 Cancer Genes and Their Mutations 2  
 Identification of Cancer Genes 2  
 Cancer Genome Investigation: Tools and Quality Controls 2  
 Somatic Alteration Classes Detected by Cancer Genome Analysis 12  
 Pathway-Oriented Models of Cancer Genome Analysis 14  
 Networks of Cancer Genome Projects 16  
 The Genomic Landscape of Cancers 18  
 The Cancer Genome and the New Taxonomy of Tumors 18  
 Cancer Genomics and Drug Resistance 20  
 Perspectives of Cancer Genome Analysis 20
- 2. Mechanisms of Genomic Instability . . . . . 23**  
*David J. Gordon, David A. Barbie, Alan D. D'Andrea, and David Pellman*  
 Basic Defenses Against Genomic Instability 23  
 Barriers to Genomic Instability 23  
 Mutations in Cancer 26  
 Mechanisms of Genome Destabilization in Human Tumors 29  
 What Causes Chromosomal Instability and Whole-Chromosome Aneuploidy? 35  
 Does Whole-Chromosome Aneuploidy Cause Cancer? 37  
 Perspectives and Implications for Cancer Therapeutics 38
- 3. Epigenetics of Cancer . . . . . 41**  
*Peter A. Jones and Karin B. Michels*  
 Epigenetic Processes 41  
 Epigenomic Changes in Cancer 43  
 The Timing of Epigenetic Alterations 44  
 Epigenetic Biomarkers for Early Detection of Cancer 44  
 Epigenetic Therapies 45  
 Problems with Epigenetic Therapies 46
- 4. Telomeres, Telomerase, and Cancer . . . . . 48**  
*Kwok-Kin Wong, Norman E. Sharpless, and Ronald A. DePinho*  
 Telomeres and Telomerase 48  
 Senescence 50  
 Telomere Maintenance and Cancer 53
- 5. Cell Signaling Growth Factors and Their Receptors . . . . . 57**  
*Lewis C. Cantley, Chris L. Carpenter, William C. Hahn, and Matthew Meyerson*  
 Signal Transduction Systems 57  
 Sensory Machinery: Ligands and Receptors 57  
 Regulation of Protein Kinases 60  
 Small-Molecule Second Messengers 63  
 Efficiency and Specificity: Formation of Multiprotein Signaling Complexes 64  
 Signaling Networks 66
- 6. Cell Cycle . . . . . 68**  
*Steven I. Reed*  
 Cell-Cycle Engine 68  
 Induction of Cell-Cycle Phase Transitions 71  
 Ubiquitin-Mediated Proteolysis 71  
 Regulation of the Cell Cycle 72  
 Cell Cycle and Cancer 76  
 MicroRNAs, the Cell Cycle, and Cancer 79  
 The Cell Cycle and Cancer Therapy 80
- 7. Mechanisms of Cell Death . . . . . 82**  
*Vassiliki Karantzis and Eileen White*  
 Apoptosis 82  
 Autophagy 87  
 Necrosis 89
- 8. Cancer Metabolism . . . . . 91**  
*Matthew G. Vander Heiden*  
 Altered Metabolism in Cancer Cells 91  
 Energetics of Cell Proliferation 93  
 Imaging Cancer Metabolism in Patients 94  
 Genetic Events Important for Cancer Influence Metabolism 95  
 Targeting Metabolism to Treat Cancer 99
- 9. Angiogenesis . . . . . 101**  
*Robert S. Kerbel and Lee M. Ellis*  
 Introduction: Origins of the Concept of Antiangiogenic Therapy for Cancer 101  
 Sequential Steps Involved in the Formation of Blood Vessel Capillaries in Tumors 101  
 Pericytes 102  
 Dysfunctional Nature of the Tumor Vasculature 102  
 Molecular Mediators of Tumor Angiogenesis: Angiogenic Stimulators and Their Receptors 103  
 Endogenous Inhibitors of Tumor Angiogenesis 105  
 A Cooperative Regulator of Tumor Angiogenesis: The Notch Receptor-DLL4 Signaling Pathway in Endothelial Cells 106  
 Strategies for Development of Antiangiogenic Drugs 106  
 Enhancement of Chemotherapy Efficacy and Other Therapeutic Modalities by Antiangiogenic Drugs 107  
 Resistance to Antiangiogenic Drugs or Treatments 108  
 Biomarkers for Tumor Angiogenesis and Antiangiogenic Therapy 109  
 Antiangiogenic/Anti-VEGF Drug-Based Clinical Trials 109  
 Looking Ahead: New Targets, New Drugs, and New Strategies for Antiangiogenic Therapy 111
- 10. Invasion and Metastasis . . . . . 113**  
*Andy J. Minn and Joan Massagué*  
 The Evolution and Pathogenesis of Metastasis 113  
 An Integrated Model for Metastasis 115  
 Selective Pressures at the Primary Tumor Driving Acquisition of Metastasis Functions 117  
 Coupling Tumorigenesis with Metastasis Initiation 119  
 Coupling Tumorigenesis with Metastasis Progression 121  
 From Metastasis Progression to Macrometastatic Colonization 122  
 Micro-RNAs and Metastasis 126
- 11. Cancer Stem Cells . . . . . 128**  
*Jean C. Y. Wang and John E. Dick*  
 Tumor Heterogeneity 128  
 Leukemia Stem Cells 129